

VITAMIN D: MOVING TOWARD EVIDENCE-BASED DECISION MAKING IN PRIMARY CARE

DECEMBER 2-3, 2014 • NATCHER AUDITORIUM

DRAFT AGENDA

DAY 1 — TUESDAY, DECEMBER 2

7:00 A.M. REGISTRATION

8:00 A.M. Welcome and Rationale for Conference
Conference Chair: *Clifford Rosen, M.D.* — Maine Medical Center Research
Institute

SESSION 1: HOW DO WE EVALUATE AND APPLY EVIDENCE FOR PRIMARY CARE DECISION MAKING?

8:10 A.M. Principles for Evaluating Evidence

8:40 A.M. Translating Evidence into Recommendations and Guidelines

9:10 A.M. Revised Standards for National Guidelines Clearinghouse

9:30 A.M. BREAK

9:45 A.M. Development of Endocrine Society Guidelines

10:15 A.M. Application of AHRQ Reports to Vitamin D Reference Values

10:45 A.M. USPSTF Recommendations on Screening Vitamin D

11:15 A.M. Panel: Perspectives on Evaluating Evidence in Primary Care Context

- Comments from Panelists
- Panel Discussion and Comments from Audience

12:15 P.M. LUNCH (ON YOUR OWN)

SESSION 2: WHAT IS THE VIEW FROM THE FRONT LINES OF CLINICAL PRACTICE?

1:30 P.M. What is the Lay of the Land for Clinical Guidance and Practitioner Tools?

1:45 P.M. Panel: What Do Clinicians Experience?

- Comments from Panelists
- Panel Discussion and Comments from Audience

SESSION 3: HOW DO WE THINK ABOUT RISK OF NUTRITIONAL INADEQUACY?

2:15 P.M. If Clinical Measures Reflect a Distribution, How Do We Deal with Concepts of
Cutpoints?

2:45 P.M. BREAK

- 3:00 P.M. Groups at Risk and Relevance for Clinical Practice
- 3:30 P.M. African American Case Study: Serum and Bone Health
- 4:00 P.M. African American Case Study: Genetic Variants—Perspective 1
- 4:30 P.M. African American Case Study: Genetic Variants—Perspective 2
- 5:00 P.M. ADJOURN

DAY 2 — WEDNESDAY, DECEMBER 3

SESSION 4: WHAT DO WE KNOW ABOUT VITAMIN D INTAKE AND SUPPLEMENT USE?

- 7:30 A.M. REGISTRATION
- 8:00 A.M. Current Exposure to Vitamin D: Supplement Use, Food Fortification
- 8:30 A.M. Changes in Serum 25(OH)D Concentrations with Amount and Nature of Intake
- 9:00 A.M. Adverse Consequences of Vitamin D Intake: Role of Observational Data and Emerging Evidence from Epidemiology
- 9:30 A.M. Sessions 3 & 4: Joint Panel Discussion—Balancing Risk and Intervention
- Comments from Panelists
 - Panel Discussion and Comments from Audience
- 10:00 A.M. BREAK

SESSION 5: WHAT ARE ISSUES SURROUNDING LABORATORY MEASUREMENT OF SERUM 25(OH)D?

- 10:15 A.M. Current State of Play and Challenges for Clinical Practice
- 10:45 A.M. Panel: What Do These Methodology Issues Mean for Clinical Practice?
- Comments from Panelists
 - Panel Discussion and Comments from Audience

SESSION 6: WHAT CAN WE SAY ABOUT TRANSLATING EVIDENCE INTO CLINICAL PRACTICE AND THE RELATED RESEARCH NEEDS?

- 11:15 A.M. Summary Panel: How Do We Develop a Roadmap for Next Steps?
- Comments from Panelists
 - Panel Discussion and Comments from Audience
- 12:00 NOON ADJOURN